MediciNova, Inc

MedicNova Inc. is a U.S.-based biopharmaceutical company focused on developing novel therapeutics for serious diseases with unmet medical needs. Its lead programs center on MN-166 (ibudilast) for neurological and inflammatory disorders and MN-001 (tipelukast) for fibrotic and metabolic diseases, with commercialization expected to rely on partners rather than an internal sales force.

−3 237,6 %

−2 928,8 %

−59,0 %

8.16

8.16

— MediciNova, Inc
%
MN-166 (ibudilast)55% Clinical-stage program targeting neurological and other disorders including MS, ALS, neuropathy, DCM, glioblastoma and ARDS prevention.
MN-001 (tipelukast)25% Clinical-stage program focused on fibrotic and metabolic disorders such as NAFLD and hypertriglyceridemia.
Research collaboration services5% Limited revenue from services performed under the Mayo Foundation agreement.
Intellectual property and licensing15% Patent portfolio and license agreements supporting current and future product candidates.

MedicNova does not currently sell approved pharmaceuticals at scale, so its direct customers are mainly research...

  • Clinical research collaboratorsprimary

    Hospitals, academic centers and research groups that help run trials and generate data for MN-166 and MN-001.

  • Strategic licensing/commercialization partnersprimary

    Pharmaceutical partners expected to help commercialize approved products outside the company’s small internal footprint.

  • Future prescribers and treatment centerssecondary

    Neurologists, specialists and hospitals that would use approved therapies if the programs succeed.

  • Payers and reimbursement systemsprimary

    Third-party payers and formularies that determine access and pricing for any approved drug.

MedicNova is headquartered in the United States and states that its commercial focus is the U.S. market...

  • •Headquartered in the United States
  • •Commercial focus on the U.S. market
  • •Clinical collaboration in the U.K. on DCM
  • •Japanese sourcing history for ibudilast capsules
  • •Foreign patents and applications support global IP

The company’s strategy is to concentrate resources on a small number of clinical programs with the highest unmet-need...

01
Advance MN-166 clinical programsshort-term

MN-166 is the core asset and spans multiple neurological indications with potential partnering value.

02
Develop MN-001 in metabolic and fibrotic diseasemedium-term

MN-001 broadens the pipeline into liver and lipid-related disorders and diversifies clinical risk.

03
Use external partners for manufacturing and commercializationshort-term

The company lacks internal sales and manufacturing scale, so partners are essential to reach market.

04
Preserve capital while funding trialsshort-term

As a loss-making biotech, cash runway and disciplined spend determine how long programs can advance.

MedicNova is exposed to the classic risks of a clinical-stage biotech: trial failure, regulatory delay, and dependence...

critical

Clinical development failure

The company’s value depends on proving safety and efficacy in ongoing trials for MN-166 and MN-001.

Scope
MN-166 and MN-001 programs
Materiality
high
high

Dependence on third-party manufacturers

API and finished product are outsourced, reducing control over quality, timing and scale-up.

Scope
Clinical and future commercial supply
Materiality
high
high

Lack of commercialization infrastructure

The company has no internal sales and marketing capability and must rely on partners or build one later.

Scope
Post-approval launch execution
Materiality
high
high

Reimbursement and pricing pressure

Even if approved, formulary access and payer controls can restrict adoption and pricing.

Scope
U.S. and international markets
Materiality
medium
medium

Competition from larger pharma and biotech firms

Competitors may reach market sooner or develop superior therapies for the same diseases.

Scope
Neurology, fibrosis and metabolic disease markets
Materiality
medium
Clinical trial accruals
Can shift expense recognition between periods
External development expense timing
Creates quarter-to-quarter volatility in operating loss
Service revenue recognition under Mayo agreement
Small but visible revenue line
Goodwill and indefinite-lived intangible impairment
Could create material non-cash write-downs
Stock-based compensation
Affects G&A and reported loss

Innoviva, Inc.

INVA · Pharmaceutical Preparations

MEDICINOVA INC

MNOV · Pharmaceutical Preparations

LivaNova PLC

LIVN · Electromedical & Electrotherapeutic Apparatus

Theriva Biologics, Inc.

TOVX · Pharmaceutical Preparations

Medicale Corp.

MCLE · Services-Health Services

Medicus Pharma Ltd.

MDCX · Pharmaceutical Preparations

: 28.4.2026